3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Gastrointestinal
2
Thoracic
1
Sarcoma
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Dermatologic
1
Conditions
Salivary Gland Neoplasms
3
Endometrial Neoplasms
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Thyroid Neoplasms
1
Testicular Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Mouth Neoplasms
1
Melanoma
1
Liver Neoplasms
1
Head and Neck Neoplasms
1
Gastrointestinal Stromal Tumors
1
Gastrointestinal Neoplasms
1
Gallbladder Neoplasms
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinosarcoma
1
Carcinoma, Renal Cell
1
Breast Neoplasms
1
Anus Neoplasms
1
Interventions
Surveys and Questionnaires
4
Nivolumab
3
pembrolizumab
2
cemiplimab
2
atezolizumab
2
amminedichloro(2-methylpyridine)platinum(II)
2
Blood Specimen Collection
2
trastuzumab deruxtecan
1
trametinib
1
repotrectinib
1
pralsetinib
1
pazopanib
1
motexafin gadolinium
1
durvalumab
1
dabrafenib
1
avelumab
1
alectinib
1
Transurethral Resection of Prostate
1
Tomography, X-Ray Computed
1
Reverse Transcriptase Polymerase Chain Reaction
1
Radiosurgery
1
Quality of Life
1
Patient-Specific Modeling
1
Oncolytic Virotherapy
1
Ocoxin
1
Observation
1
Mass Screening
1
MLN 8237
1
Immune Checkpoint Inhibitors
1
Hyperspectral Imaging
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Gastrointestinal Neoplasms
×
trastuzumab deruxtecan
×
Head & Neck
×
Clear all
NCT07124000
2026-06-01
DP-04
AstraZeneca
Recruiting
100 enrolled